Researchers at Roswell Park Comprehensive Cancer Center found that mitochondrial unfolded protein response—a unique longevity function of mitochondria—could be a target for the treatment and management of metastatic, resistant, or recurrent prostate cancer.
The phase III ARANOTE trial, investigating Nubeqa (darolutamide) plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, has met its primary endpoint of radiological progression-free survival. Nubeqa plus ADT demonstrated a statistically significant and clinically meaningful increase in rPFS compared to placebo plus ADT.
